New Delaware Chapter 11 Filing – Argos Therapeutics, Inc.

Save as PDF

Argos Therapeutics, Inc. (f/k/a Merix Bioscience, Inc.) has filed a petition for relief under chapter 11 in the Bankruptcy Court for the District of Delaware (Case No. 18-12714).  According to the First Day Declaration, Argos, based in Durham, N.C., is an immune-oncology company developing immunotherapeutic drugs using its proprietary Arcelis® platform.  The First Day Declaration explains that Argos has filed as a result of negative results in a phase 3 clinical trial for one of its products.  As a result, Argos—which also has products in three other Phase 2 trials—is seeking to sell substantially all of its assets under section 363 of the Bankruptcy Code, with Cellscript, LLC serving as stalking horse purchaser.  No claims and noticing agent has been proposed.  The case has been assigned to the Honorable Kevin J. Carey.

Contact Norman L. Pernick, G. David Dean or Myles R. MacDonald for more information regarding this matter.


As the law continues to evolve on these matters, please note that this article is current as of date and time of publication and may not reflect subsequent developments. The content and interpretation of the issues addressed herein is subject to change. Cole Schotz P.C. disclaims any and all liability with respect to actions taken or not taken based on any or all of the contents of this publication to the fullest extent permitted by law. This is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Do not act or refrain from acting upon the information contained in this publication without obtaining legal, financial and tax advice. For further information, please do not hesitate to reach out to your firm contact or to any of the attorneys listed in this publication.

Join Our Mailing List

Stay up to date with the latest insights, events, and more

Check all areas of law you are interested in receiving e-newsletters and alerts about:(Required)
This field is for validation purposes and should be left unchanged.

Our Practices



Our Industries